ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive: Au et al. was aimed at the relationship between SNPs of ABCB1 and imatinib-resistance in chronic myelocytic leukemia patients, suggesting the TKIs is likely to change the SNPs of ABC transporter to develop drug resistance [98].